Inhibition of VEGF signaling in the tumor microenvironment has been reported to improve cytotoxic CD8+ T-cell activity via upregulation of cytokine secretion both as monotherapy and in combination with immune checkpoint blockade (47). The gene discussed is CD8A; the disease is neoplasm.